Table 1 Patient characteristicsa
Early breast cancer | Metastatic breast cancer |
|---|---|
Number of patients enrolled = 25 | Number of patients enrolled = 25 |
Age, years | Age, years |
Median (range), 59 (26 to 76) | Median (range), 59 (36 to 83) |
ECOG performance status, n (%) | ECOG performance status, n (%) |
0 24 (96%) | 0 8 (32%) |
1 1 (4%) | 1 13 (52%) |
2 0 (0%) | 2 4 (16%) |
Histology, n (%) | Histology, n (%) |
Ductal 22 (88%) | Ductal 20 (80%) |
Lobular 3 (12%) | Lobular 1 (4%) |
Other 0 (0%) | Unknown 4 (16%) |
Menopausal status, n (%) | Menopausal status, n (%) |
Premenopausal 8 (32%) | Premenopausal 4 (16%) |
Perimenopausal 1 (4%) | Perimenopausal 1 (4) |
Postmenopausal 16 (64%) | Postmenopausal 20 (80%) |
Hormone receptor status, n (%) | Hormone receptor status, n (%) |
ER-positive/PR-positive 11 (44%) | ER-positive/PR-positive 11 (44%) |
ER-positive/PR-negative 6 (24%) | ER-positive/PR-negative 3 (12%) |
ER-negative/PR-positive 1 (4%) | ER-negative/PR-positive 2 (8%) |
ER-negative/PR-negative 7 (28%) | ER-negative/PR-negative 9 (36%) |
Tumour size, n (%) | Number of disease sites, n (%) |
1 to 1.9 cm (T1) 6 (24%) | 1 7 (28%) |
2 to 5 cm (T2) 16 (64%) | 2 9 (36%) |
>5 cm (T3) 1 (4%) | 3 4 (16%) |
Unknown 2 (8%) | ≥4 5 (20%) |
Tumour grade, n (%) | Line of treatment, n (%) |
I 2 (8%) | First 11 (44%) |
II 9 (36%) | Second 7 (28%) |
III 13 (52%) | ≥Third 7 (28%) |
Unknown 1 (4%) | Â |
| Â | Primary breast cancer at presentation, n (%) |
| Â | Early 9 (36%) |
Positive nodes, n (%) | Metastatic 16 (64%) |
0 (N0) 11 (44%) | Â |
1 to 3 (N1) 9 (36%) | Visceral disease, n (%) |
4 to 9 (N2) 2 (8%) | Yes 13 (52%) |
≥10 (N3) 2 (8%) | No 12 (48%) |